StreetAlpha.app
Home › Stocks › NPCE

NeuroPace Inc (NPCE)

$7.95
▼ −2.33%
LAST CLOSE · NOV 20

NeuroPace makes the RNS System, an implanted brain device that treats seizures in people with epilepsy. It last closed at $7.95 on Nov 20, down 2.33% on the day. The next earnings report for NPCE is expected around Tue, Mar 2, 2027, after the close. For the quarter ended Sep 2026, NPCE reported EPS of -$0.10 on revenue of $23.1M, with revenue down 1.1% from a year ago. Over its last 8 reports the stock moved an average of 13.0% the session after earnings. Over the last 12 months NPCE insiders bought $302K of stock on the open market and sold $399K, according to SEC Form 4 filings.

AI Auto Pilots
Is NPCE in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold NPCE.

Key Stats

Last 12 months
Results
Revenue
$106.7M
+29.2% vs a year ago
Net income
−$18.9M
−17.7% margin
EPS (diluted)
−$0.56
Free cash flow
−$12.4M
−11.6% margin
Valuation
Market cap
$273.9M
34.5M shares
P/E
–
No P/E while losing money
Price to sales
2.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$10.2M
At Sep 30
Debt
$59.2M
At Sep 30
Shareholder equity
$11.5M
Shares outstanding
34.5M
At Nov 10
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $45.2M$45.2MFY2021FY2022: $45.5M$45.5MFY2022FY2023: $65.4M$65.4MFY2023FY2024: $79.9M$79.9MFY2024FY2025: $100.0M$100.0MFY2025

From NPCE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Mar 2
Estimated date · After the close
Reported EPS
-$0.10
Quarter ended Sep 2026
Year ago EPS
-$0.11
Same quarter last year
Revenue
$23.1M
−1.1% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.17Dec '24Mar 2025: -$0.21Mar '25Jun 2025: -$0.26Jun '25Sep 2025: -$0.11Sep '25Dec 2025: -$0.08Dec '25Mar 2026: -$0.20Mar '26Jun 2026: -$0.18Jun '26Sep 2026: -$0.10Sep '26Latest -$0.10
Revenue by quarter
Dec 2024: $21.5MDec '24Mar 2025: $22.5MMar '25Jun 2025: $19.5MJun '25Sep 2025: $23.4MSep '25Dec 2025: $38.8MDec '25Mar 2026: $22.1MMar '26Jun 2026: $22.8MJun '26Sep 2026: $23.1MSep '26Latest $23.1M
How NPCE moved after its last 8 reports
Average move the session after a report ±13.0%
Nov 12, 2026After the close−37.1%
Aug 11, 2026After the close−3.3%
May 12, 2026After the close+0.1%
Mar 3, 2026After the close+0.9%
Nov 4, 2025After the close+38.1%
Aug 12, 2025After the close+2.1%
May 13, 2025After the close+20.5%
Mar 4, 2025After the close−2.4%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on NPCEStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on NPCE: 0 upgrades, 0 downgrades, 0 initiations
Cantor FitzgeraldTarget cut
Nov 16  

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on NPCE
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on NPCE

Technical Analysis

NPCE · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 42% below its 20 day and 58% below its 50 day average. It is 83% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 26), oversold. The nearest support is the Pivot S1 at $7.76, and the nearest resistance the Pivot at $8.02.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 12.3%/day
Key levels
$19.6052 week high+146.5%
$14.57200 day average+83.3%
$13.77100 day average+73.2%
$13.27Swing high (Oct 13)+66.9%
$12.5750 day average+58.1%
$11.2920 day average+42.0%
$8.22Pivot R1+3.4%
$8.02Pivot+0.9%
$7.95Last close
$7.76Pivot S1−2.4%
$5.4652 week low−31.3%
$5.46Swing low (Nov 13)−31.3%
Indicators
RSI (14)25.65Oversold below 30Oversold
MACD-1.35Below its signal lineBearish
Stochastic31.2Middle of its rangeNeutral
ADX (14)26.3Trending down
Williams %R-70.6Oversold below −80, overbought above −20Neutral
CCI (20)-106.5Oversold below −100, overbought above 100Oversold
Rate of change−36.4%Change over 10 sessionsBearish
ATR (14)$0.98Typical daily range, 12.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NPCE

What happened before

See how NPCE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow NPCE usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How NPCE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for NPCEHow many large options trades hit NPCE, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

NPCE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▼48 buying vs 67 selling
  • ▲Held by funds +0.7 pts
  • ▼Funds holding -8
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding105113−7.1%
In funds' top 1000–
Held by funds77.8%77.1%+0.7 pts
New / increased14 / 3418 / 48−27.3%
Reduced / sold out44 / 2336 / 18+24.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NPCE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

NPCE Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$302K3 buys · 3 insiders
Sold$399K1 sale · 1 insider
Cluster buy: 3 insiders bought $302K between Nov 17 and Nov 18.
2025-12 sold $399K2026-11 bought $302KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 18R Scott HuennekensDirectorBuy12,500$8.29$104K
Nov 17Joel BeckerCEOBuy11,891$8.35$99K
Nov 17Patrick F. WilliamsCFOBuy11,891$8.34$99K
Dec 15, 2025Martha MorrellChief Medical OfficerSale25,000$15.97$399K
May 14, 2025Orbimed Advisors LLC10% ownerSale168,136$15.85$2.7M
Feb 21, 2025Martha MorrellChief Medical OfficerSale78,334$13.72$1.1M
Every insider buy and sale for NPCE over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See NPCE insider trades →

From SEC Form 4 filings by NPCE's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NPCE is in one of them and how their past NPCE trades turned out.

NPCE in the AI portfolios
Loading…

NPCE News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NPCE in an article yet. Here's the latest on the wider market.

NPCE in the news

About NeuroPace

NeuroPace makes medical devices for people with epilepsy, focusing on those whose seizures are not controlled by medication. Its main product is the RNS System, an implant that monitors the brain's electrical activity and delivers small electrical pulses when it detects a seizure starting. The devices are sold mainly to epileptologists and neurosurgeons who treat patients at specialized epilepsy centers in the United States. The company is based in Mountain View, California.

Headquarters
Mountain View, CA